NextCure Provides Business Update
NXTCBELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position.
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NXTC(NASDAQ:NXTC) BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on Monday, September 8th, at 4:00 pm ET.
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
NXTCBELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported second quarter 2025 financial results.
NextCure And LigaChemBio Announces They Will Present Trial In Progress Poster For LNCB74, A B7-H4 Targeted Antibody-Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumors At American Society of Clinical Oncology 2025
NXTCNextCure Q1 EPS $(0.39) Beats $(0.40) Estimate
NXTCHC Wainwright & Co. Reiterates Buy on NextCure, Maintains $3 Price Target
NXTCHC Wainwright & Co. Reiterates Buy on NextCure, Lowers Price Target to $3
NXTCNextCure FY 2024 GAAP EPS $(1.99) Misses $(1.92) Estimate
NXTCNextCure Doses First Patient Dosed In Phase 1 Study Of LNCB74 (For Treating Multiple Cancers
NXTCNextCure Highlights Presentation Of Data Demonstrating That NC605 Resulted In Enhanced Generation Of Quality Bone With Better Mechanical Properties
NXTCNextCure Reports Preclinical Data For LNCB74 And Additional Clinical Biomarker Data For NC410 Combo At Society For Immunotherapy Of Cancer Annual Meeting
NXTC